MentionFox
Home › Executive changes › DNA X, Inc.
Leadership changes · SONM · SEC Form 8-K, Item 5.02

Leadership changes at DNA X, Inc. (2026)

Before you join, sell to or invest in DNA X, Inc.

MentionFox check on DNA X, Inc.: only 2 sources on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/dna-x

Check DNA X, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about DNA X, Inc.?

Who joined and who left DNA X, Inc. (SONM)? 2 appointments and 2 departures reported from 2026-02-05 to 2026-02-10, each cited to the company's own filing.

As of November 14, 2026, DNA X, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from February 5, 2026 to February 10, 2026, naming 2 appointments and 2 departures. The latest filing names Mike Mulica, appointed (Form 8-K, February 10, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

LYTTON LAURENCE W also filed stake reports on 28 other companies ↓

Sell to companies like DNA X, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes4
In (appointed)2
Out (departing)2
Latest filing2026-02-10

DNA X, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-02-05 to 2026-02-10. They name 4 people, with 2 appointments and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as DNA X, Inc. files it.

Also on the record for DNA X, Inc.

DateRecordFigureOur pageSource
August 13, 2026Stake report, Schedule 13G/A, by LYTTON LAURENCE W6.8% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G/A, by LYTTON LAURENCE W8.1% of the class5%+ stakesSource
February 20, 2026Stake report, Schedule 13D, by DNA Holdings Venture Inc.19.9% of the class5%+ stakesSource
February 17, 2026Stake report, Schedule 13G/A, by 1 Main Capital Management, LLC—5%+ stakesSource
February 17, 2026Stake report, Schedule 13G/A, by LYTTON LAURENCE W9.96% of the class5%+ stakesSource
January 23, 2026Stake report, Schedule 13G/A, by Streeterville Capital LLC—5%+ stakesSource
December 18, 2025Stake report, Schedule 13G, by Streeterville Capital LLC9.9% of the class5%+ stakesSource
December 15, 2025Acquired DNA X LLC$1.20MAcquisitionSource
November 14, 2025Stake report, Schedule 13G/A, by 1 Main Capital Management, LLC8.2% of the class5%+ stakesSource
November 14, 2025Stake report, Schedule 13G/A, by L1 Capital Global Opportunities Master Fund, Ltd.—5%+ stakesSource
November 14, 2025Stake report, Schedule 13G/A, by LYTTON LAURENCE W7.8% of the class5%+ stakesSource
November 7, 2025Stake report, Schedule 13G/A, by CVI Investments, Inc.—5%+ stakesSource

Selling to them or working with them? See who runs DNA X, Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on DNA X, Inc. and the records around it.

DNA X, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on DNA X, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on DNA X, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on DNA X, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    14 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The newest 12 of 17 records.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-02-10In2026-02-098-K, 2026-02-10
2026-02-05OutDirector8-K, 2026-02-05
2026-02-05Out2026-01-298-K, 2026-02-05
2026-02-05InDirector8-K, 2026-02-05

Why did they leave? What the filings say

For 1 of the 2 named departures below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.

Who leads DNA X, Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to DNA X, Inc.?

New leaders reset buying decisions — get the Full Report on DNA X, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch DNA X, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the Director at DNA X, Inc., with the record behind each one.

Find candidates like Director at DNA X, Inc.

Every change, in the filing's words

Filed 2026-02-10 · 8-K

Appointed: Mike Mulica, effective 2026-02-09

Effective February 9, 2026, Mike Mulica, executive chairman of DNA X, Inc. (formerly, Sonim Technologies, Inc.), a Delaware corporation (the " Company "), was appointed as the Company's acting chief executive officer and, accordingly, was designated as the Company's principal executive officer.

Also stated in this filing

  • Mr. Mulica, 62, has held various roles at the Company since April 2021, most recently as its executive chairman as of October 16, 2025.
  • CFO Employment Agreement On February 9, 2026, the Company and Clay Crolius, the Company's Chief Financial Officer, entered into a second amendment to Mr. Crolius's employment agreement, dated December 8, 2023 (the "CFO Amendment").
Filed 2026-02-05 · 8-K

Departing: Peter Liu, Director

On January 30, 2026, Peter Liu, chief executive officer of DNA X, Inc. (formerly, Sonim Technologies, Inc.) a Delaware corporation (the " Company "), notified the Company's Board of Directors (the " Board ") that he was resigning from the office of chief executive officer of the Company and as a director on the Board, effective as of the same date.

Departing: Charles Becher, effective 2026-01-29

On February 3, 2026, Charles Becher, chief commercial officer of the Company, notified the Board that he was resigning from the office of chief commercial officer of the Company, effective as of January 29, 2026.

Appointed: Scott Walker, Director

Director Appointment On January 30, 2026, following Mr. Liu's resignation from the Board, the Board appointed Scott Walker to serve on the Board as a director.

Also stated in this filing

  • As required by that certain employment agreement by and between Mr. Liu and the Company, dated as of December 8, 2023, as amended by that certain first amendment to employment agreement, dated April 2, 2025 (as amended, the "Liu Employment Agreement"), the separation and release agreement entered into by Mr. Liu and the Company (the "Liu Separation and Release Agreement") provided for Mr. Liu's general release of claims against the Company.
  • Additionally, the Liu Separation and Release Agreement provided that the total cash severance payment owed to Mr. Liu pursuant to the Liu Employment Agreement ($855,000) is now payable in two tranches: the first payable three days after his execution of the Liu Separation and Release Agreement and the second payable on March 15, 2026.
  • The Liu Employment Agreement previously provided that the cash severance payment would be paid in one lump sum payment not more than thirty days following separation.

Tools for this story

Each opens in a new tab, filled in for DNA X, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/dna-x
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
DNA X, Inc. executive departures 2026. MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/dna-x